ECSP088712A - Compuestos de n-formil-hidroxilamina - Google Patents

Compuestos de n-formil-hidroxilamina

Info

Publication number
ECSP088712A
ECSP088712A EC2008008712A ECSP088712A ECSP088712A EC SP088712 A ECSP088712 A EC SP088712A EC 2008008712 A EC2008008712 A EC 2008008712A EC SP088712 A ECSP088712 A EC SP088712A EC SP088712 A ECSP088712 A EC SP088712A
Authority
EC
Ecuador
Prior art keywords
compounds
formil
hydroxylamine compounds
disclosed
formyl hydroxylamine
Prior art date
Application number
EC2008008712A
Other languages
English (en)
Inventor
Kwangho Lee
Jennifer Leeds
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088712A publication Critical patent/ECSP088712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se dan a conocer novedosos compuestos de N-formil-hidroxilamina y sus derivados. Estos compuestos de N-formil-hidroxilamina inhiben la peptidil-desformilasa (PDF), una enzima presente en los procariotes. Los compuestos son útiles como antimicrobianos y antibióticos. Los compuestos de la invención exhiben una inhibición selectiva de la peptidil-desformilasa contra otras metaloproteinasas, tales como MMPs. También se dan a conocer métodos de preparación y uso de los compuestos.
EC2008008712A 2006-03-03 2008-09-02 Compuestos de n-formil-hidroxilamina ECSP088712A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77937706P 2006-03-03 2006-03-03

Publications (1)

Publication Number Publication Date
ECSP088712A true ECSP088712A (es) 2008-10-31

Family

ID=38510154

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008712A ECSP088712A (es) 2006-03-03 2008-09-02 Compuestos de n-formil-hidroxilamina

Country Status (19)

Country Link
US (1) US20090062537A1 (es)
EP (1) EP1994027A2 (es)
JP (1) JP2009529008A (es)
KR (1) KR20080095895A (es)
CN (1) CN101395148A (es)
AU (1) AU2007226715A1 (es)
BR (1) BRPI0708524A2 (es)
CA (1) CA2643267A1 (es)
CR (1) CR10251A (es)
EC (1) ECSP088712A (es)
GT (1) GT200800170A (es)
IL (1) IL193524A0 (es)
MA (1) MA30285B1 (es)
MX (1) MX2008011128A (es)
NO (1) NO20084069L (es)
RU (1) RU2008139192A (es)
TN (1) TNSN08344A1 (es)
WO (1) WO2007106670A2 (es)
ZA (1) ZA200807054B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
CN101869563B (zh) * 2010-07-02 2011-11-16 华东师范大学 含4-亚甲基吡咯烷的肽脱甲酰基酶抑制剂
TW201249824A (en) * 2011-03-09 2012-12-16 Glaxosmithkline Llc Peptide deformylase inhibitors
CN103159660B (zh) * 2011-12-08 2016-07-06 天津市国际生物医药联合研究院 (2r)-1-(2-甲基-3-(甲氧基(甲基)氨基)-丙酰基)吡咯烷-2-羧酸及其应用
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
BR112014015582A8 (pt) 2012-02-24 2017-07-04 Hoffmann La Roche compostos antivirais
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
DK3102568T3 (en) * 2014-02-06 2018-10-08 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN-M1 RECEPTOR AGONISTS
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20220029783A (ko) 2015-01-20 2022-03-08 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
MX2017011919A (es) 2015-03-18 2018-05-22 Arvinas Inc Compuestos y metodos para la degradacion mejorada de proteinas especificas.
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
IL304982A (en) 2016-11-01 2023-10-01 Arvinas Operations Inc PROTACS Targeted Tau-Protein and Related Methods of Use
EP3548483A4 (en) 2016-12-01 2020-06-10 Arvinas Operations, Inc. TETRAHYDRONAPHTHALINE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS AN ESTROGEN RECEPTOR-DEGRADING AGENT
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
AU2017382406A1 (en) 2016-12-23 2019-04-18 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
JP7266526B6 (ja) 2017-01-26 2024-02-15 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
AU2019249231B2 (en) 2018-04-04 2022-04-21 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
KR20220119094A (ko) 2019-12-19 2022-08-26 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
EP4323352A1 (en) 2021-04-16 2024-02-21 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
AU2004216178B2 (en) * 2003-02-21 2008-07-03 Novartis Ag Chemical process for the preparation of intermediates to obtain N-formyl hydroxylamine compounds

Also Published As

Publication number Publication date
IL193524A0 (en) 2009-08-03
WO2007106670A3 (en) 2008-01-24
AU2007226715A1 (en) 2007-09-20
CR10251A (es) 2008-10-27
MA30285B1 (fr) 2009-03-02
CN101395148A (zh) 2009-03-25
WO2007106670A2 (en) 2007-09-20
NO20084069L (no) 2008-12-03
BRPI0708524A2 (pt) 2011-05-31
TNSN08344A1 (en) 2009-12-29
JP2009529008A (ja) 2009-08-13
GT200800170A (es) 2008-10-29
ZA200807054B (en) 2009-10-28
US20090062537A1 (en) 2009-03-05
MX2008011128A (es) 2008-09-08
CA2643267A1 (en) 2007-09-20
EP1994027A2 (en) 2008-11-26
RU2008139192A (ru) 2010-04-10
KR20080095895A (ko) 2008-10-29

Similar Documents

Publication Publication Date Title
ECSP088712A (es) Compuestos de n-formil-hidroxilamina
AR056360A1 (es) Compuestos de n- formil- hidroxilamina
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
CY1118104T1 (el) Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
GT200600117A (es) Nuevos compuestos farmaceuticos
WO2007077186A8 (en) Pdf inhibitors
BRPI0511133A (pt) uso de galacto-oligossacarìdeos e polifrutose
BR112013014119A8 (pt) Novos moduladores e métodos de uso
UY30748A1 (es) Compuesto0s novedosos
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CO6351784A2 (es) Formas cristalinas de dimetoxi-docetaxel y sus procedimeintos de preparacion
IN2012DN02580A (es)
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
RS53868B1 (en) ATP-BINDING CASSETTE TRANSPORT MODULATORS
BRPI0717266A2 (pt) Derivados de oxindol
UA94412C2 (en) Glutamate aggrecanase inhibitors
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
NO20054790D0 (no) Anvendelse av B7-113 som et immunoregulatorisk middel
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
DK2344486T3 (da) Alkylthiazolcarbamatderivater, fremstilling deraf og anvendelse deraf som hæmmere af enzymet FAAH
EA201000070A1 (ru) Модуляторы калликреина 7
ATE528290T1 (de) Spiroindolinon-derivate